Merck KGaA presses Versum investors to back its $5-9B acquisition bid
Category: #headlines  By Mateen Dalal  Date: 2019-03-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck KGaA presses Versum investors to back its $5-9B acquisition bid

Versum management rejected Merck KGaA’s all-cash offer in favor of rival Entegris’ January offer

Merck KGaA, based out of Darmstadt in Germany, has reportedly urged the shareholders of U.S. electronic materials company Versum Materials, to pressurize its management for considering Merck’s offered proposal for takeover against a rival bid.

In an open letter to the investors of Versum, Merck called on them to advise the Board of Versum that its shareholders would not be supporting an acquisition by Entegris owing to a superior proposal by the German pharmaceutical giant. It also informed the investors that an offer to directly engage with Versum for understanding the rationale behind the Board’s determination was not accepted.

Officials from Versum had not yet offered any comments on the reports, however the company has made known that it remains committed towards a no-cash merger with Entegris, which had been agreed to in January this year. Apparently, Merck’s unsolicited cash bid valued at $5.9 billion, which was a non-binding proposal made to Versum management and had not been put out to shareholders, was recently rejected by the company.

Reports confirm that Entegris had made an offer to acquire Versum Materials in January, in an agreed all-stock transaction that valued the equity of Versum at nearly $4 billion at the time. Their merger would lead to the creation of a substantially large chemical supplier to the currently under-pressure semiconductor industry.

Merck has supposedly disclosed that it is planning to keep the main Tempe, Arizona site of Versum as the U.S. hub for a combined electronic materials business in the country. It suggested that the premium valuation represented in its proposal is immediate and certain, without the need for achieving any synergies and without any of the substantial ongoing integration, market or operational risks reflected in the value of Entegris’ stock consideration.

One of the investors of Versum has indicated that if Merck wants to oust an existing deal agreed upon, it would need to give shareholders more assurance with regard to its offer.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...